Pfizer Stock Price, News & Analysis

Pfizer (NYSE: PFE) and Sangamo Therapeutics (NASDAQ: SGMO) have released updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, a gene therapy for severe hemophilia A. At 104 weeks, patients in the highest dose cohort exhibited a mean factor VIII activity of 25.4% with no annualized bleeding in the first year post-infusion. However, the Phase 3 AFFINE trial has encountered a clinical hold by the FDA following observations of elevated FVIII levels in treated patients. The ongoing studies aim to evaluate long-term efficacy and safety of this investigational therapy.

Pfizer Inc. (NYSE: PFE) has announced a quarterly cash dividend increase to $0.40 per share for the first quarter of 2022. This dividend is payable on March 4, 2022, to shareholders on record by January 28, 2022. This marks the 333rd consecutive dividend payout by the company. Pfizer's leadership, including Dr. Albert Bourla, emphasized that this increase reflects strong financial performance and confidence in the company’s product portfolio and research pipeline.

Pfizer Inc. (NYSE: PFE) announced that the European Commission approved its oral medication Cibinqo® (abrocitinib) for treating moderate-to-severe atopic dermatitis in adults. Cibinqo, a Janus kinase 1 inhibitor, is available in 100 mg and 200 mg doses, with a 50 mg dose for patients with renal impairment. The approval is backed by five clinical studies with over 2,800 patients, showing significant symptom improvement versus placebo and a favorable safety profile. This marks a vital treatment innovation for patients suffering from this chronic condition.

The U.S. FDA has expanded the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine booster, now available for individuals aged 16 and older. Administered at least six months post-primary series, the booster has shown a 95% efficacy in combating symptomatic COVID-19 compared to non-booster recipients. Pfizer and BioNTech plan to submit a supplemental Biologics License Application to formalize this authorization. The companies will continue supplying vaccines under existing agreements with the U.S. government through April 2022.

Pfizer and BioNTech announced that three doses of their COVID-19 vaccine effectively neutralize the Omicron variant, while two doses show significantly reduced effectiveness. A booster dose increases neutralizing antibody titers by 25-fold against Omicron, similar to the response against the wild-type virus. Despite two doses providing some protection against severe disease, a third dose is recommended for optimal protection. The companies are developing a variant-specific vaccine for Omicron, expected by March 2022, without impacting their production capacity of four billion doses in 2022.

Pfizer Inc. (NYSE: PFE) will hold a live webcast on December 17, 2021, at 8:30 a.m. EST, featuring discussions about the Pfizer-BioNTech COVID-19 vaccine and an oral antiviral treatment candidate. Interested parties can access the webcast via www.pfizer.com/investors. A Q&A session will follow the presentations, with pre-registration advised. The webcast replay will be available for at least 90 days. Pfizer continues to emphasize its commitment to improving healthcare and addressing COVID-19 challenges.

ViiV Healthcare has released survey data for World AIDS Day, revealing significant stigma and misinformation about HIV. Conducted by The Harris Poll among 5,047 adults in the U.S., UK, Australia, and Portugal, the survey found that 88% of respondents perceive ongoing negative attitudes towards individuals living with HIV. It also highlighted that 76% were unaware that effective treatment can prevent HIV transmission. ViiV emphasizes the need for ongoing anti-stigma campaigns, showcasing collaborative efforts like HIV in View.

NiKang Therapeutics has formed a clinical trial collaboration with Pfizer (PFE) to evaluate NKT2152, targeting advanced clear cell renal cell carcinoma (ccRCC). The trial will assess NKT2152 in combination with Pfizer’s palbociclib and sasanlimab for patients unresponsive to prior treatments. NiKang will sponsor the study while Pfizer co-funds it and supplies drugs at no cost. The collaboration aims to leverage complementary pathways for effective therapy. Currently, NKT2152 is in a phase 1/2 trial to determine safety and efficacy.

Pfizer Inc. (NYSE: PFE) invites investors to join a webcast discussion featuring Bob Smith, Vice President of Pfizer Rare Disease, at the 4th Annual Evercore ISI HealthCONx Conference. The event is scheduled for December 1, 2021, at 5:10 p.m. EST. Interested parties can access the webcast on www.pfizer.com/investors. A transcript and replay will be available within 24 hours of the event's conclusion, accessible for at least 90 days on the same site.